What is Lifesci Capital's Estimate for ELVN Q2 Earnings?

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Stock analysts at Lifesci Capital issued their Q2 2025 EPS estimates for shares of Enliven Therapeutics in a note issued to investors on Thursday, May 29th. Lifesci Capital analyst S. Slutsky expects that the company will earn ($0.54) per share for the quarter. The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.95) per share. Lifesci Capital also issued estimates for Enliven Therapeutics' Q3 2025 earnings at ($0.57) EPS and Q4 2025 earnings at ($0.58) EPS.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06).

Several other equities research analysts also recently issued reports on the stock. HC Wainwright raised their target price on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. Jones Trading cut their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $37.25.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN traded up $0.10 during mid-day trading on Friday, hitting $17.84. The stock had a trading volume of 290,192 shares, compared to its average volume of 261,996. Enliven Therapeutics has a twelve month low of $13.30 and a twelve month high of $30.03. The stock has a market cap of $875.39 million, a price-to-earnings ratio of -9.39 and a beta of 1.07. The company's 50 day simple moving average is $18.01 and its 200 day simple moving average is $20.96.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ELVN. Polar Capital Holdings Plc raised its holdings in Enliven Therapeutics by 267.6% in the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock valued at $53,768,000 after acquiring an additional 1,739,668 shares during the period. Boxer Capital Management LLC bought a new position in shares of Enliven Therapeutics during the fourth quarter worth approximately $15,106,000. Janus Henderson Group PLC increased its holdings in shares of Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after purchasing an additional 290,153 shares during the period. FMR LLC increased its holdings in shares of Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company's stock worth $146,157,000 after purchasing an additional 199,692 shares during the period. Finally, Pictet Asset Management Holding SA increased its holdings in shares of Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company's stock worth $21,877,000 after purchasing an additional 135,969 shares during the period. 95.08% of the stock is owned by institutional investors.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the transaction, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at $20,629,865.36. This represents a 1.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $16.18, for a total transaction of $52,585.00. Following the completion of the transaction, the chief financial officer now directly owns 23,000 shares in the company, valued at approximately $372,140. This represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 86,111 shares of company stock valued at $1,643,398 in the last three months. 29.20% of the stock is currently owned by company insiders.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.